Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"ABL Europe","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABL and Odimma Therapeutics Enter Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Capital Grand Est","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Odimma Therapeutics Secures \u20ac2 Million to Complete the Preparation of Its First-in-Man Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Odimma Therapeutics

    Menu

    Odimma Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Odimma Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Odimma Therapeutics Secures €2 Million to Complete the Preparation of Its First-in-Man Clinical Trial

              Details:

              The financing will secure the preparation on Odimma's First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.

              Lead Product(s): ODI-2001

              Therapeutic Area: Oncology Product Name: ODI-2001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Capital Grand Est

              Deal Size: $2.2 million Upfront Cash: Undisclosed

              Deal Type: Financing May 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Odimma Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA

              Details:

              Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Recipient: Touchlight

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Odimma Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ABL and Odimma Therapeutics Enter Development Agreement

              Details:

              ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing personalized neoantigens.

              Lead Product(s): ODI-2001

              Therapeutic Area: Oncology Product Name: ODI-2001

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: ABL Europe

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY